ID30255A - METHODS FOR PREVENTING OR DELAYING REVASCULARIZATION BASED ON CATERATER - Google Patents

METHODS FOR PREVENTING OR DELAYING REVASCULARIZATION BASED ON CATERATER

Info

Publication number
ID30255A
ID30255A IDW20010902A ID20010902A ID30255A ID 30255 A ID30255 A ID 30255A ID W20010902 A IDW20010902 A ID W20010902A ID 20010902 A ID20010902 A ID 20010902A ID 30255 A ID30255 A ID 30255A
Authority
ID
Indonesia
Prior art keywords
caterater
delaying
preventing
methods
revascularization
Prior art date
Application number
IDW20010902A
Other languages
Indonesian (id)
Inventor
Donald Michael Black
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22289955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID30255(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ID30255A publication Critical patent/ID30255A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Surgical Instruments (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
IDW20010902A 1998-09-30 1999-07-08 METHODS FOR PREVENTING OR DELAYING REVASCULARIZATION BASED ON CATERATER ID30255A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10245798P 1998-09-30 1998-09-30

Publications (1)

Publication Number Publication Date
ID30255A true ID30255A (en) 2001-11-15

Family

ID=22289955

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010902A ID30255A (en) 1998-09-30 1999-07-08 METHODS FOR PREVENTING OR DELAYING REVASCULARIZATION BASED ON CATERATER

Country Status (35)

Country Link
US (1) US20080119561A1 (en)
EP (1) EP1117392B1 (en)
JP (1) JP2002525321A (en)
KR (1) KR20010079955A (en)
CN (1) CN1197565C (en)
AP (1) AP1708A (en)
AT (1) ATE260100T1 (en)
AU (1) AU768474B2 (en)
BG (1) BG105471A (en)
BR (1) BR9914098A (en)
CA (1) CA2343299C (en)
CZ (1) CZ20011035A3 (en)
DE (1) DE69915084T2 (en)
DK (1) DK1117392T3 (en)
EA (1) EA007427B1 (en)
EE (1) EE200100199A (en)
ES (1) ES2214872T3 (en)
HK (1) HK1042436A1 (en)
HR (1) HRP20010236A2 (en)
HU (1) HUP0103648A3 (en)
ID (1) ID30255A (en)
IL (2) IL141953A0 (en)
IS (1) IS5889A (en)
NO (1) NO20011615L (en)
NZ (1) NZ510500A (en)
OA (1) OA11787A (en)
PL (1) PL346980A1 (en)
PT (1) PT1117392E (en)
SI (1) SI1117392T1 (en)
SK (1) SK4122001A3 (en)
TR (1) TR200100901T2 (en)
UA (1) UA73292C2 (en)
WO (1) WO2000018395A1 (en)
YU (1) YU23901A (en)
ZA (1) ZA200102230B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078747A1 (en) * 2000-04-18 2001-10-25 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
CA2414783A1 (en) * 2000-07-14 2002-01-24 Warner-Lambert Company Treatment of eating disorders using carboxyalkylethers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
WO1995013063A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
US5957916A (en) * 1994-05-25 1999-09-28 The Trustees Of Columbia University In The City Of New York Myocardial revascularization through the endocardial surface using a laser
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
CN1217656C (en) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 Method and pharmaceutical composition for regulating lipid concentration
SE506272C2 (en) * 1996-03-18 1997-11-24 Paul Edholm Method and apparatus for determining image position and angle of view in an X-ray image
IL117702A0 (en) * 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
WO1998001100A2 (en) * 1996-07-09 1998-01-15 Merck & Co., Inc. Method for treating homozygous familial hypercholesterolemia
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
AU4975099A (en) 2000-04-17
EA200100370A1 (en) 2001-10-22
KR20010079955A (en) 2001-08-22
DE69915084T2 (en) 2004-07-22
ZA200102230B (en) 2002-06-18
EP1117392B1 (en) 2004-02-25
WO2000018395A1 (en) 2000-04-06
CA2343299C (en) 2008-04-01
DK1117392T3 (en) 2004-06-14
JP2002525321A (en) 2002-08-13
ES2214872T3 (en) 2004-09-16
HRP20010236A2 (en) 2002-04-30
OA11787A (en) 2005-07-26
TR200100901T2 (en) 2001-08-21
NZ510500A (en) 2003-10-31
CA2343299A1 (en) 2000-04-06
CN1197565C (en) 2005-04-20
IS5889A (en) 2001-03-14
PT1117392E (en) 2004-07-30
UA73292C2 (en) 2005-07-15
YU23901A (en) 2003-07-07
EE200100199A (en) 2002-06-17
EP1117392A1 (en) 2001-07-25
BG105471A (en) 2001-12-31
PL346980A1 (en) 2002-03-11
SK4122001A3 (en) 2002-06-04
NO20011615D0 (en) 2001-03-29
AU768474B2 (en) 2003-12-11
ATE260100T1 (en) 2004-03-15
HUP0103648A2 (en) 2003-08-28
IL141953A0 (en) 2002-03-10
CN1342072A (en) 2002-03-27
DE69915084D1 (en) 2004-04-01
HUP0103648A3 (en) 2003-10-28
US20080119561A1 (en) 2008-05-22
IL141953A (en) 2006-07-05
EA007427B1 (en) 2006-10-27
AP1708A (en) 2007-01-10
AP2001002112A0 (en) 2001-06-30
SI1117392T1 (en) 2004-06-30
CZ20011035A3 (en) 2001-10-17
HK1042436A1 (en) 2002-08-16
NO20011615L (en) 2001-04-24
BR9914098A (en) 2001-07-31

Similar Documents

Publication Publication Date Title
DE69938817D1 (en) CREATING PROCEDURE
DE69916360D1 (en) airfoil
TR199900531A3 (en) Pirazolopyrimidines and pirazolotriazines.
DE69943006D1 (en) heatsink
DE69903088T2 (en) corkscrew
ATE252547T1 (en) MATRIXMETALLOPROTEINASE INHIBITORS
ID28624A (en) DESCRIPTION 2-FENILPIRAN-4-ON
DE69904933T2 (en) LOCKING DEVICE
ID23196A (en) DESCRIPTION FOR LAMPUFLOURESEN
FR2777750B1 (en) SEASONING
ID30255A (en) METHODS FOR PREVENTING OR DELAYING REVASCULARIZATION BASED ON CATERATER
DE59900726D1 (en) LOCKING DEVICE
DE69810450D1 (en) locking device
DE59906422D1 (en) locking device
DE69930852D1 (en) Prenyl INHIBITORS
DE69909568D1 (en) locking device
DE69818799D1 (en) locking device
FI981207A0 (en) demodulation method
ES1039261Y (en) PERFECTED CASE.
FI982277A0 (en) Step
NO994785L (en) Lock
FI3582U1 (en) Rotator
SE9804251D0 (en) locking component
ATA124998A (en) LOCKING DEVICE
SE9804356D0 (en) Locking device